$ABCL

U.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.

UBS initiates coverage of AbCellera Biologics with a Buy rating and a $18 price target. The stock is currently trading at $12.54, up 4.37% in pre-market. The rating is based on valuation, EPS revisions, and visibility metrics.

AbCellera (ABCL) will present Phase 1/2 data for ABCL635, a non-hormonal treatment for menopausal vasomotor symptoms, at The Menopause Society’s 2026 Annual Meeting. The data includes safety, pharmacokinetics, and efficacy results from ongoing trials. ABCL635 targets NK3R, a protein involved in body temperature regulation.

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

Iovance (IOVA) surged 31% to a 2-year high after raising its 2026 revenue outlook to $410M-$420M, exceeding consensus. AbCellera (ABCL) gained 6% with JPMorgan initiating coverage with an 'Overweight' rating and $17 target. CrowdStrike (CRWD) rose 1% after announcing plans to integrate with OpenAI's marketplace. Retail sentiment improved for IOVA and ABCL but remained bearish for CRWD.

U.S. stock futures were flat on Tuesday. Summit Therapeutics (SUM) rose 17.1% after AstraZeneca's $2B investment. Fair Isaac (FICO) fell 15% due to FHFA mortgage pricing changes. CarMax (KMX) gained 3.7% on strong Q2 earnings. AAR Corp. (AIR) surged 6.9% after a $4B acquisition and earnings beat. Netflix (NFLX) rose 1.4% after a Deutsche Bank upgrade.

Abcellera Biologics (ABCL) stock rose 2.1% pre-market after JPMorgan initiated coverage with an Overweight rating and $17 price target, citing confidence in its clinical-stage pipeline. The stock has gained over 400% in a year, driven by strong Phase 2 data for its menopause drug, ABCL635. Analysts broadly see upside from current levels, with a consensus price target above $14.23.

JPMorgan initiated coverage of AbCellera Biologics with an 'Overweight' rating and a $17 price target, according to the company. The stock was trading at $13.92 in pre-market, up 9.61% on the day.

Goldman Sachs resumed coverage of AbCellera Biologics (NASDAQ:ABCL) with a Neutral rating and a $13.00 price target. The company reported Q2 revenue of $4.1M, missing estimates, but announced successful Phase 2 trial results for ABCL635, leading Truist to raise its price target to $30. AbCellera has a strong cash position and recently launched a $200M stock offering.

AbCellera Biologics (ABCL) stock rose 121% in 3 months, outpacing its industry. The surge was driven by positive phase II data for ABCL635, a treatment for menopause symptoms, and new partnerships. The study met primary endpoints, showing significant reductions in hot flash frequency and severity. Additional data is expected in October. The company also reported strong financial stability and investor confidence.